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A B S T R A C T
Targeted therapies, including antibodies, are becoming increasingly important in cancer
therapy. Important limitations, however, are that not every patient benefits from a specific
antibody therapy and that responses could be short-lived due to acquired resistance. In
addition, targeted therapies are quite expensive and are not completely devoid of side-
effects. This urges the need for accurate patient selection and response monitoring.
An important step towards personalizing antibody treatment could be the implementation
of theranostics. Antibody theranostics combine the diagnostic and therapeutic potential of
an antibody, thereby selecting those patients who are most likely to benefit from antibody
treatment. This review focuses on the clinical application of theranostic antibodies in
oncology. It provides detailed information concerning the suitability of antibodies for
theranostics, the different types of theranostic tests available and summarizes the efficacy
of theranostic antibodies used in current clinical practice. Advanced theranostic applica-
tions, including radiolabeled antibodies for non-invasive functional imagining, are also ad-
dressed. Finally, we discuss the importance of theranostics in the emerging field of
personalized medicine and critically evaluate recent data to determine the best way to
apply antibody theranostics in the future.
ª 2014 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
1. Introduction
Targeted therapies are becoming increasingly important for
the treatment of cancer. These therapies are designed to
specifically interferewith aberrant targets or pathways of can-
cer cells, which is in contrast to the generalized cytotoxic ef-
fects of standard chemotherapy (Teng et al., 2013). The two
main types of targeted therapy are the monoclonal antibodies
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Table 1 e Registered unconjugated therapeutic antibodies for cancer treatment.
Antibody Antibody type Target antigen Antigen category FDA-approved indicationsa Theranostic antibody test
Trastuzumab (Herceptin) Humanized HER2 Growth factor Breast cancer (HER2-positive); as single agent or
combined with chemotherapy for adjuvant
or palliative treatment
Gastric or gastro-oesophageal junction carcinoma
(HER2-positive); as first-line treatment in combination
with cisplatin and capecitabine or 5-fluorouracil
HER2 IHCc (e.g. HercepTest)
Cetuximabb (Erbitux) Chimeric EGFR Growth factor Head and neck cancer; combined with radiation
therapy for initial treatment of locally or regionally
advanced disease or as single agent for patients
who failed prior platinum-based therapy
Colorectal cancer (EGFR-positive); palliative
treatment of pretreated metastatic disease
Colorectal cancer: EGFR IHCc
(e.g. EGFR pharmDx kit)
Panitumumabb (Vectibix) Human EGFR Growth factor Colorectal cancer (EGFR-positive); as single
agent for pretreated metastatic disease
EGFR IHCc (e.g. EGFR
pharmDx kit)
Bevacizumab (Avastin) Humanized VEGF Vascular target Colorectal cancer; for first-line and second-line
treatment of metastatic disease, in
conjunction with 5-fluorouracil-based chemotherapy
Non-small cell lung cancer (NSCLC);
first-line treatment of advanced disease,
in combination with carboplatin and paclitaxel,
in patients who have not yet received chemotherapy
Glioblastoma; as single agent in adult patients
for second line treatment
Renal cell carcinoma (RCC); in conjunction
with IFNa to treat metastatic disease
No (under development)
Rituximab (Rituxan) Chimeric CD20 Hematopoetic
differentiation
antigen
Non-Hodgkin’s lymphoma (NHL) (CD20-positive);
for B cell NHL and maintenance therapy for
untreated follicular NHL
Chronic lymphocytic leukemia
NHL: CD20 ELISA/
flow cytometry
EGFR: Epidermal Growth Factor Receptor; VEGF: Vascular Endothelial Growth Factor, IHC: immuno-histochemistry, ELISA: enzyme-linked immunosorbent assay.
a Based on cancer.gov (January 2014) and (Scott et al., 2012).
b Not recommended for colorectal cancer patients whose tumors express mutated KRAS.
c In addition to IHC, the predictive value of HER2 and EGFRmRNA expression or gene amplification asmeasured by polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH) has also
been studied in the clinic. Because this review focuses specifically on the theranostic applications of antibodies in oncology, we did not further consider these applications.
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Table 2 e Conjugated therapeutic antibodies for cancer treatment.
Antibody Target antigen Antibody type Conjugate type Emittera Indicationsb,c Theranostic antibody test
90Y-Ibritumomab
tiuxetan (Zevalin)
CD20 Murine Radionuclide
(yttrium-90)
b FDA: non-Hodgkin’s lymphoma (NHL);
for relapsed or refractory, low-grade or
follicular B cell NHL or previously
untreated follicular NHL in patients
achieving a partial or complete
response to first-line chemotherapy
Safety: biodistribution and dosimetry
prior to therapy (111In- Ibritumomab tiuxetan)
131I-Tositumomab
(Bexxar)
CD20 Murine Radionuclide
(iodine-131)
b and g FDA: NHL (CD20-positive); for relapsed
or refractory, low-grade, follicular or
transformed NHL
CD20 ELISA/flow cytometry
Safety: biodistribution and dosimetry
prior to therapy (low-dose Bexxar)
177Lu/90Y -J591 PSMA Humanized Radionuclide
(lutetium-177/yttrium-90)
b and g/b Research: prostate cancer Research: 111In-J591 for
response prediction
177Lu eGirentuximab
(cG250)
CAIX Chimeric Radionuclide
(lutetium-177)
b and g Research: renal cell carcinoma (RCC) Research: 111In-Girentuximab
for response prediction
Gemtuzumab
ozogamicin (Mylotarg)
CD33 Humanized Toxin (calicheamicin) n.a. FDA withdrawn: acute myeloid leukemia
(AML) (CD33-positive);
for relapsed patients >60 years not
suited for other chemotherapy
CD33 ELISA/flow cytometry
Trastuzumab emtansine
(T-DM1, Kadcyla)
HER2 Humanized Toxin (emtansine) n.a. FDA: breast cancer (HER2-positive);
metastatic
HER2 IHC (e.g. HercepTest)
Research: 89Zr-trastuzumab
to exclude non-responders
a b-emission is solely used for radioimmunotherapy, while g-emission can be used for imaging.
b FDA-approved indications are specifically pointed out (FDA), others are under clinical investigation (research).
c Based on cancer.gov (January 2014) and (Scott et al., 2012).
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(mAbs) and tyrosine kinase inhibitors (TKIs). The major ad-
vantages of these targeted molecules are their tumor speci-
ficity and low toxicity profile. Important limitations,
however, are that (i) not every patient benefits from a specific
targeted treatment and (ii) responses could be short-lived due
to acquired resistance (Gerber, 2008). This urges the need for
accurate patient selection and response monitoring.
A promising strategy towards improving personalized
medicine is the implementation of theranostics. Theranostics
combine the therapeutic (“thera”) and diagnostic (“nostic”) po-
tentials of a certain compound. Prior to therapy, the com-
pound is used in a diagnostic test to determine whether the
drug will (potentially) exert a therapeutic effect, making it a
powerful tool for personalizing cancer treatment. Because it
operates on the molecular level, it could be more accurate
for response prediction and/or monitoring than more general
tumor characteristics such as tumor morphology (e.g. CT and
MRI) or metabolism (e.g. 18F-FDG-PET).
This review focuses on the clinical application of theranos-
tic antibodies in oncology. It provides detailed information
concerning antibody suitability for theranostics, the different
types of theranostic tests available and summarizes the effi-
cacy of theranostic antibodies currently used in clinical prac-
tice. In addition, more advanced theranostic applications,
including the use of radiolabeled antibodies are addressed.
Finally, we discuss the importance of theranostics in the
emerging field of personalized medicine and critically eval-
uate recent data to determine the best way to apply antibody
theranostics in the future.
2. Antibodies used for theranostic applications
To date, several mAbs have been approved by the Food and
Drug Administration (FDA) for the treatment of cancer. Anti-
bodies specifically target antigens expressed on the cell
Table 3 e Characteristics of theranostic antibody tests.
Theranostic antibody assay Standard use Advantages Disadvantages
Immunohistochemistry Solid tumors  Simple to perform
 Low costs
 Routinely available
 Requires invasive biopsies
 No whole body target expression
 No information about
target accessibility
 Variability (tissue
handling/fixation)
 Semi-quantitative
 Subjective interpretation
 Membranous expression
often hard to define
Enzyme-linked
immunosorbent
assay (ELISA)
Hematological
tumors
 Minimally invasive
(blood sampling)
 Simple to perform
 Low costs
 Routinely available
 Can define
membranous expression
 Quantitative
 No whole body
target expression
 No information about
target accessibility
 Subjective interpretation
(arbitrary thresholds)
Flow cytometry Hematological
tumors
 Minimally invasive
(blood sampling)
 Relatively simple to perform
 Relatively low costs
 Available in most laboratories
 Can define
membranous expression
 Very accurate
 Quantitative
 No whole body
target expression
 No information about
target accessibility
 Subjective interpretation
(arbitrary thresholds)
Functional imaging
(immuno-PET/
immuno-SPECT)
Solid and
hematological
tumors
 Minimally invasive
(IV injection)
 Can define
membranous expression
 Very accurate
 Quantitative
 Whole body
target expression
 Target accessibility
taken into account
 Can be performed repetitively
 Specific equipment required
 Specific expertise required
 High costs
 Tracers must be prepared
shortly before injection
PET: positron emission
tomography, SPECT: single
photon emission computed
tomography, IV: intravenous.
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membrane or ligands (e.g. bevacizumab, Section 4.3) and can
either be administered unconjugated (Table 1) or conjugated
to cytotoxic moieties such as radionuclides or toxins to in-
crease efficacy (Table 2) (Gerber, 2008). Because target expres-
sion is usually a prerequisite for antibody response, one could
base patient selection on the expression of the target antigen
(Fleuren et al., 2011; Heskamp et al., 2013b). However, for
many therapeutic antibodiesmere target expression appeared
not sufficient to predict response in all patients. For unconju-
gated or naked antibodies it is essential that, in addition to its
presence on the tumor, the target antigen is also involved in
tumor progression. But even when this is the case, tumors
only rarely depend on a single regulatory pathway for growth
and survival because of their molecular complexity and het-
erogeneity. Parallel activation of other receptors or mutations
in downstream pathways are not rare events. This could at
least in part explain the lack of response in tumors with
apparent oncogenic target expression (De Palma and
Hanahan, 2012). Because physiological factors (e.g. vasculari-
zation, hypoxia, intratumoral pressure) can impede adequate
antibody targeting to the tumor, these should also be taken
into account when predicting response (Heldin et al., 2004;
Jain, 1999). In addition, the antibody Fc-portion can evoke an
additional anti-tumor response by triggering antibody-
dependent cellular cytotoxicity (ADCC) or complement depen-
dent cytotoxicity (CDC) processes. This underscores the
complexity of finding a suitable predictive biomarker and indi-
cate that theranostic applications should be interpreted with
caution.
Not every overexpressed membranous tumor protein is a
potential candidate for treatment with unconjugated anti-
bodies as functional involvement is also required. Neverthe-
less, high target expression on tumor cells may be sufficient
for predicting response for conjugated antibodies. However,
also with conjugated antibodies, target accessibility should
be taken into account and for these constructs it is of utmost
importance to also determine target expression levels on non-
tumor tissue to avoid side-effects.
3. Types of theranostic antibody tests
Because target expression is usually a prerequisite for
response, it seems a logical first step to base patient selection
on target expression. Although several comments can be
made on this design (e.g. involvement of other pathways),
detection of the target protein is expected to at least exclude
primarily resistant patients. At present, several different diag-
nostic methods exist to screen for target expression, which all
have their specific advantages and limitations as discussed
below and summarized in Table 3.
Figure 2 e Heterogeneous distribution of 124I-girentuximab in RCC lesions. (A and B) Axial, sagittal, and coronal CT (top), PET (middle), and
fused PET/CT (bottom) images of a patient with clear cell renal cancer with relatively homogeneous intratumoral distribution of the radiolabeled
antibody (arrows) (A) and a patient with large, centrally necrotic clear cell renal cancer with marked heterogeneity (arrows) (B). (C) Axial CT (top),
PET (middle), and fused PET/CT (bottom) images of a patient with advanced clear cell renal cancer. Antibody distribution within the primary
tumor is heterogeneous (arrows), whereas distribution within metastatic nodes is relatively homogeneous (arrowheads). This figure was originally
published in JNM; reprinted with permission (Pryma et al., 2011) (adapted).
Figure 1 e Whole body biodistribution of a radiolabeled antibody.
Whole-body coronal PET/CT images of 124I-girentuximab, acquired
5 days after antibody infusion. The specific uptake of the antibody can
be seen in the left renal tumor (arrow), which is expressing the CAIX
antigen. The concentration of the radiolabeled antibody in a tumor
can be determined quantitatively. Left: CT, middle: PET, right:
fused PET/CT. This figure was originally published in Nat Rev
Cancer; reprinted with permission (Scott et al., 2012) (adapted).
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3.1. Immunohistochemistry
Immunohistochemistry (IHC) is currently themost commonly
used procedure to perform antibody theranostics for solid tu-
mors. The antibody can be used to detect target expression on
tumor tissue by IHC. When the section is scored positive for
target expression, the same antibody can subsequently be
used for therapy. A well-known example of this approach is
the HercepTest (Section 4.1). IHC has the advantages of being
simple to perform, cheap, and readily available in most pa-
thology laboratories. There are however numerous variables,
such as tissue handling and fixation and antibody sensitivity
and specificity. Because slides are not scored by automated
computer systems, inter-observer interpretation and vari-
ability can also affect the accuracy of test results (Cuadros
and Villegas, 2009). Because antibodies can only target
extracellularly-expressed antigens, it would be appropriate
to specifically screen for membranous expression. This is
however difficult to determine by conventional IHC, often
due to high cytoplasmic receptor expression. Other limita-
tions include the lack of information obtained about in vivo
target accessibility and the need for invasive biopsies. More-
over, receptor expression is determined on a limited number
of sections of a single biopsy, often formalin-fixed paraffin-
embedded (FFPE) archival tissue. Because tumors are usually
very heterogeneous, patients often present with multiple le-
sions and target expression levels can change over time (for
instance during therapy), multiple biopsies would be required
for adequate antigen testing, which in most cases is clinically
unfeasible.
3.2. Hematological analysis
For hematological cancers, immuno-assays are commonly
used for theranostic approaches, such as enzyme-linked
immunosorbent assay (ELISA) or flow cytometry. An ELISA
uses antibodies to determine the amount of antigen in serum,
plasma or other body fluids (Kenny and Dunsmoor, 1983).
Flow cytometry is a laser-based technology measuring
antigen expression in single cells from a suspension. For
biomarker detection with flow cytometry, antibodies can be
used to determine the expression of a particular antigen on
blood cell subtypes (Brown and Wittwer, 2000). A well-
known example of a hematological theranostic assay is
CD20 testing by ELISA or flow cytometry prior to rituximab
therapy (Section 4.4). ELISAs are in general quick and easy to
perform, readily available, can define membranous expres-
sion levels and can be analyzed quantitatively. Flow cytome-
try measures single cells, is quantitative, very accurate and
can measure specific membranous target expression. Disad-
vantages of both techniques include the subjective interpreta-
tion of results due to arbitrary threshold settings, so there is
no straightforward difference between positive and negative
samples. Also with these techniques, only a fraction of tumor
cells is measured thus no whole body tumor expression
pattern is determined.
3.3. Immuno-PET/immuno-SPECT
For both solid and hematological tumors, target expression
levels can be determined in vivo using molecular imaging
methods, such as immuno-positron emission tomography
(PET) and immuno-single photon emission computed tomog-
raphy (SPECT). For both techniques, an antibody is labeled
with a radionuclide (positron or g-emitter) and injected intra-
venously. The 3D distribution of the radiolabeled antibody is
subsequently visualized with a SPECT or PET scanner. With
these molecular imaging techniques, several limitations of
conventional IHC and serum assays can be circumvented. Ad-
vantages include non-invasive screening and visualization of
specific membranous target expression. Moreover, these
whole body scans enable target visualization in the whole tu-
mor, inmultiple lesions simultaneously and take target acces-
sibility into account (Figures 1 and 2). These scans can be
performed repetitively to asses target modulation over time,
for instance during (targeted) treatment. Because theranostic
molecular imaging approaches are relatively new, they have
not yet been implemented as standard diagnostic tests.
Figure 3 e 111In-bevacizumab imaging in a RCC patient before and after anti-angiogenic treatment. Anterior and posterior 111In-bevacizumab
scans at baseline (A) and after 4 weeks of treatment with the TKI sorafenib (angiogenesis inhibitor; 400 mg twice daily) (B). A marked decrease of
111In-bevacizumab uptake is observed (arrows). This figure was originally published in JNM; reprinted with permission (Desar et al., 2010)
(adapted).
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Results from clinical trials are however encouraging, as for
instance shownwith indium-111 (111In)-labeled-girentuximab
imaging prior to lutetium-177 (177Lu)-girentuximab radioim-
munotherapy (RIT) (Section 5.3). Disadvantages include the
use of specific equipment and expertise, tracers should be pre-
pared shortly before injection and costs are higher than with
conventional methods (Heskamp et al., 2013b).
4. Theranostic antibodies in current clinical practice
4.1. Trastuzumab (Herceptin)
One of the most widely used theranostic approaches in clin-
ical practice is the HercepTest to determine HER2 expression
levels in breast cancer (BC) prior to trastuzumab therapy.
HER2, also known as Neu or ErbB2, is a member of the
epidermal growth factor receptor (EGFR) family and plays an
important role in BC pathogenesis. HER2 is overexpressed in
20e30% of all BCs and trastuzumab showed activity only
against HER2-overexpressing tumors. An increasing number
of studies suggest that HER2 status is more important than
the histologic BC type (Cuadros and Villegas, 2009; Heskamp
et al., 2013b). Notably, trastuzumab would not have been
approved for BC treatment if studies were performed upon a
general population of BC patients without prior identification
of HER2 expression. HER2 is also overexpressed in subsets of
ovarian, lung, gastric and oral cancers, and all newly diag-
nosed gastric cancers are also tested for HER2 by IHC to select
patients eligible for trastuzumab therapy (de Mello et al., 2013;
Meric-Bernstam and Hung, 2006). Unfortunately, however,
only 30% of HER2-positive BCs actually respond to trastuzu-
mab therapy. This may be explained by either inaccurate
HER2 assessments or that these tumors not strictly depend
onHER2-mediated growth signaling, for instance due tomuta-
tions in downstream pathways (e.g. PI3K). Furthermore, HER2
expression can differ between primary tumors and metasta-
ses, and this technique does not take target accessibility into
account (De Palma and Hanahan, 2012; Heskamp et al., 2013b).
Consequently, several approaches have been developed to
determine HER2 expression levels in vivo, with promising re-
sults so far. Several clinical studies indicated that 111In-trastu-
zumab SPECT and copper-64 (64Cu)-labeled or zirconium-89
(89Zr)-labeled trastuzumab PET are feasible to identify HER2-
positive lesions in patients with primary and metastatic BC
(mBC) (Dijkers et al., 2010; Perik et al., 2006; Tamura et al.,
2013). Although the exact predictive value of these imaging
modalities for trastuzumab response remains to be investi-
gated, they have great potential. In mice, 111In-pertuzumab
(a HER2 dimerization inhibitor) SPECT sensitively imaged
HER2 downregulation during trastuzumab treatment in an
in vivo human BC model, illustrating the feasibility of moni-
toring HER2 expression levels during HER2-mediated treat-
ment (McLarty et al., 2009).
4.2. Cetuximab (Erbitux) and panitumumab (Vectibix)
Cetuximab and panitumumab both target EGFR, also known
as HER1. EGFR plays an important role in proliferation, migra-
tion and survival of tumor cells. Similar to HER2-testing, also
for EGFR a diagnostic IHC test (EGFR pharmDX Kit) was devel-
oped and approved to aid in identifying colorectal cancer
(CRC) patients eligible for cetuximab or panitumumab treat-
ment (Ensinger and Sterlacci, 2008). However, although EGFR
is broadly expressed in metastatic CRC (mCRC), only 10% of
patients respond to cetuximab. In those tumorswith apparent
EGFR expression but no response to cetuximab or panitumu-
mab, additional signal transduction pathways can be active.
Clinical studies indicated that tumors harboring mutations
in KRAS, a downstream effector protein in the EGFR-
signaling cascade, show negligible responses to cetuximab
despite elevated EGFR levels. Consequently, current clinical
practice in CRC is to screen for KRAS mutations, and only
KRAS wildtype tumors are considered for EGFR-targeted ther-
apies (De Roock et al., 2010). Other studies further demon-
strated that the effect of cetuximab is independent of the
degree of EGFR expression in the tumor. Remarkably, cetuxi-
mab even showed activity in EGFR-negative CRC patients
(Chung et al., 2005; Han, 2011). Thus, EGFR overexpression is
not a reliable predictor of EGFR-antibody efficacy. One poten-
tial explanation for this discrepancy could simply be inconsis-
tent methodology and interpretation of EGFR IHC expression
(section 3.1.). Several studies reported variability in EGFR
staining depending on the tissue fixation technique used,
possibly leading to false-negative samples (Liu and
Carpenter, 1993; Ong et al., 1990; Stein and Staros, 1996).
Also, most EGFR analyses have been performed on archival
Figure 4 e 111In-R1507 immuno-SPECT and immunohistochemical
IGF-1R expression in mice with subcutaneous bone sarcoma
xenografts. 111In-R1507 immuno-SPECT/CT scans (A) and IGF-1R
expression levels of corresponding tumors (B) in mice with bone
sarcoma xenografts. Xenografts with high (OS-1), intermediate (EW-
5), or no (EW-8 and OS-33) response to treatment with the IGF-1R
antibody R1507 were selected. Images were acquired 3 days post
injection of 111In-R1507. This figure was originally published in Clin
Cancer Res; reprinted with permission (Fleuren et al., 2011) (adapted).
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primary tumor specimens that may have been kept for
months to years before assessing EGFR levels. A dramatic
decline in EGFR staining intensity has been reported with
increased storage time of tissue samples, resulting in many
more EGFR-negative scores in older specimens (Atkins et al.,
2004). An additional concern is that EGFR expression in meta-
static tumor specimens can differ significantly from EGFR
expression in the corresponding primary tumor (Johnson
et al., 1997). Because of tissue availability, the primary tumor
is frequently used to establish the patient’s EGFR status, but
it is the metastases that are being treated with cetuximab
(Chung et al., 2005).
Also for EGFR, several attempts weremade to visualize this
receptor in vivowithmolecular imaging techniques. Promising
results were obtained with 111In-cetuximab SPECT and 64Cu-
cetuximab and 89Zr-cetuximab PET in in vivo cancer models,
although liver and skin uptake was also observed (Aerts
et al., 2009; Corcoran and Hanson, 2013; Hoeben et al., 2011).
Moreover, skin toxicity appeared a surrogate marker for
cetuximab activity, implying an anti-tumor effect when skin
EGFR saturation occurs (Burtness et al., 2005). Accordingly,
with 111In-cetuximab SPECT in lung carcinoma patients, tu-
mors were only imaged when higher doses of cetuximab
were administered (Divgi et al., 1991). A phase I trial investi-
gating the predictive value of 89Zr-cetuximab PET to cetuxi-
mab therapy in stage IV cancer patients was initiated
recently, including a loading dose of 400 mg/m2 cetuximab
(NCT00691548). Another recent study investigates the predic-
tive value of 89Zr-cetuximab PET prior to chemoradiation
with cetuximab or cisplatin in head and neck cancer patients
(Heukelom et al., 2013)(NCT01504815).
4.3. Bevacizumab (Avastin)
Bevacizumab is an antibody directed against Vascular Endo-
thelial Growth Factor-A (VEGF-A), which plays a central role
in inducing the formation of new blood vessels (angiogenesis).
VEGF is a ligand that specifically binds to the VEGF receptor
(VEGFR). Bevacizumab is currently approved (alone or com-
bined with other drugs) for the treatment of mCRC, non-small
cell lung cancer (NSCLC), renal cell carcinoma (RCC) and recur-
rent glioblastoma. Response to bevacizumab is also observed
in only a subset of patients and the overall clinical benefit is
limited. Consequently, extensive clinical biomarker studies
have been performed (Lambrechts et al., 2013). Many studies
addressed the possible predictive role of circulating VEGF-A
levels by conventional methods, but inconsistent results
were found. In NSCLC, breast, ovary, and endometrium cancer
studies response rates in patients with high VEGF-A levels
were significantly higher in the bevacizumab arm than in
the placebo arm. Many other studies however failed to
observe such an effect (Lambrechts et al., 2013). A recent
extensive meta-analysis evaluating 1816 patients from phase
III CRC, NSCLC, and RCC trials confirmed that pretreatment
VEGF-A levels are a prognostic rather than a predictivemarker
(Hegde et al., 2013). However, a novel ELISA with a preference
to detect short VEGF-A isoforms could be superior for
response prediction. mBC and pancreatic cancer patients
with high baseline VEGF-A expression levels, as measured
with this novel ELISA, exhibited improved progression-free
survival (PFS) and/or overall survival (OS) upon bevacizumab
treatment (Lambrechts et al., 2013). Also in advanced gastric
cancer, patients with high baseline plasma VEGF-A levels
exhibited improved OS compared to patients with low VEGF-
A levels (Van Cutsem et al., 2012). In randomized CRC, NSCLC,
and RCC studies, no such correlation was observed, possibly
due to differences in sampling techniques (Lambrechts et al.,
2013). These results indicate that circulating VEGF levels
may be of importance towards predicting bevacizumab
response, but stress the importance of applying the appro-
priate methodology to assess target expression levels.
Several studies investigated the feasibility to visualize tu-
mor VEGF expression in patients using molecular imaging
techniques, and some even tried to link this to bevacizumab
(or other angiogenesis inhibitors) response (Figure 3). 111In-
bevacizumab SPECT visualized VEGF expression in various
malignancies, including CRC, RCC and melanoma and 89Zr-
bevacizumab PET visualized primary BC (Desar et al., 2010;
Gaykema et al., 2013; Nagengast et al., 2011; Scheer et al.,
2008). There was however no straightforward correlation be-
tween radiolabeled bevacizumab uptake and tumor VEGF-A
expression as determined by conventional methods (in situ
hybridization/ELISA), suggesting that other factors play a
role in bevacizumab targeting, such as vascular volume,
vascular permeability and/or interstitial fluid pressure. In
melanoma patients, bevacizumab treatment resulted in a
decrease in 111In-bevacizumab tumor targeting, which could
be due to both therapeutic VEGF-blocking and bevacizumab-
induced vascular changes, since bevacizumab-induced
vascular changes can hamper tumor uptake of antibodies
(Arjaans et al., 2013; Heskamp et al., 2013a; Nagengast et al.,
2011). Although these results indicate that bevacizumab imag-
ing might aid in optimizing bevacizumab therapies, to date no
studies have been performed to determine whether bevacizu-
mab imaging is predictive to bevacizumab therapy.
4.4. Rituximab (Rituxan)
Rituximab was the first therapeutic mAb approved by the FDA
for the treatment of cancer. Rituximab is directed against the
cell surface marker CD20, which is expressed on B-lympho-
cytes and approved for the treatment of non-Hodgkin’s lym-
phoma (NHL). Beneficial effects have also been reported in
chronic lymphocytic leukemia (CLL) in combination with
chemotherapy (Okroj et al., 2013). Also for rituximab, patients
are selected based on CD20 expression levels, which can be
measured by ELISA or flow cytometry. Again, its predictive
value is not straightforward (Smith, 2003; Tran et al., 2010).
While rituximab is effective in more than 50% of CD20-
positive follicular NHL patients, it is less effective in other
CD20-positive lymphoma subtypes, with activity in only
10e15% of CD20-expressing small lymphocytic lymphomas
(McLaughlin et al., 1998). This may partially be explained by
interpretation of diagnostic results. For example, a positive
flow cytometric sample is typically determined as having
>30% of cells above the cut-off. Thus even in a CD20-
positive lymphoma, many cells may have low or no expres-
sion. No or loss of CD20 expression is associated with rituxi-
mab resistance (Sugimoto et al., 2009). CLL and small
lymphocytic lymphoma have faint CD20 staining,
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corresponding to a lower rituximab response than follicular
lymphoma. Mantle cell and diffuse-large-cell lymphoma,
however, have similar or even higher CD20 expression levels
than follicular lymphoma, but lower response rates, thus
staining intensity alone does not predict response (Smith,
2003). Therefore, other mechanisms must be involved
affecting rituximab response, although the exact underlying
resistance mechanisms are yet unknown.
Rituximab has been labeled with various radioactive com-
pounds for either imaging or therapeutic RIT (Section 5.1),
depending on the radioisotope used. Iodine-131 (131I)-labeled
rituximab SPECT visualized CD20-positive cells in NHL pa-
tients, although these studies primarily focused on hemato-
logic toxicity due to subsequent rituximab-RIT (Section 5.1)
(Boucek and Turner, 2005; Leahy et al., 2006). In four patients
with highly CD20-positive primary central nervous system
lymphomas (PCNSL), iodine-123 (123I)-labeled rituximab
SPECT revealed very low tumor accumulation up to 48 h
post-injection, most likely because rituximab cannot pass
the blood brain barrier (BBB), thus these tumors are unlikely
to respond to rituximab treatment despite apparent CD20
expression (Dietlein et al., 2005). This exemplifies the impor-
tance of target accessibility instead of solely investigating
target expression levels with conventionalmethods. Although
there is at present no clinical study specifically linking pre-
treatment radiolabeled-rituximab tumor uptake levels to rit-
uximab therapy response, clinical imaging results so far
indicate that molecular imaging approaches could be more
predictive of response than conventional methods.
4.5. Antibodies against novel targets
Two novel promising targets for various cancers are the
Insulin-like Growth Factor-1 Receptor (IGF-1R) and MET
(Fleuren et al., 2013; Pollak, 2012). Numerous clinical trials
have been performed with various IGF-1R antibodies in carci-
nomas and sarcomas. Unfortunately, despite some spectac-
ular responses, the majority of patients are resistant to IGF-
1R-targeted antibody therapy (Basu et al., 2011). However,
these studies were performed upon a heterogeneous group
of patients without prior identification of a predictive
response biomarker. Nevertheless, IGF-1R expression as
determined by IHC cannot be an accurate predictor of
response, since in Ewing sarcomas IGF-1R is expressed in
virtually all tumors, but the majority of patients are IGF-1R-
therapy resistant (Scotlandi et al., 2011; van de Luijtgaarden
et al., 2013). Molecular IGF-1R imaging might be more
adequate as exemplified in a preclinical bone sarcoma study.
Here, 111In-R1507 SPECT was able to differentiate the degree
of response to the IGF-1R antibody R1507, while IGF-1R IHC
could not, highlighting the importance of selecting the appro-
priate predictive test and warranting further clinical studies
(Figure 4) (Fleuren et al., 2011).
Although themajority of MET-targeting drugs are TKIs, the
MET antibody ornatuzumab (MetMab) showed promising (pre)
clinical results (Catenacci et al., 2011). High immunohisto-
chemical MET expression was an indicator for ornatuzumab
efficacy in combined trials (Sharma and Adjei, 2011). At pre-
sent, two MET-antibodies have been radiolabeled (89Zr-DN30
and 125I-met3) and clearly visualized MET-expressing
xenografts in mice, showing the feasibility of MET-imaging
and encouraging further clinical (biomarker) studies (Hay
et al., 2003; Perk et al., 2008).
5. Conjugated theranostic antibodies in current
clinical practice
5.1. 90Y-Ibritumomab tiuxetan (Zevalin) and 131I-
Tositumomab (Bexxar)
Zevalin and Bexxar are, like rituximab, antibodies directed
against the CD20 antigen (Section 4.4) and approved for NHL
treatment. Unlike rituximab, these are murine antibodies
and conjugated to therapeutic b-emitting radionuclides
(yttrium-90 (90Y) and 131I, respectively) for RIT. Although there
are differences between Zevalin and Bexxar, such as different
murine mAbs, radioisotopes and in vivo behavior, they share
similar toxicity and efficacy profiles (Nowakowski and
Witzig, 2006). Zevalin or Bexxar RIT is combined with unla-
beled rituximab treatment to prevent excessive uptake of
the radiolabeled antibodies in the spleen and bone marrow.
One advantage of RIT over regular immunotherapy is its ca-
pacity to actually kill tumor cells instead of solely inhibiting
proliferation. Secondly, the radioisotope delivers radiation
not only to tumor cells binding the antibody, but also to neigh-
boring cells inaccessible to the antibody or with insufficient
antigen expression (cross-fire effect). The additive efficacy of
Zevalin and Bexxar RIT over unconjugated rituximab has
been demonstrated in various studies. In a randomized con-
trol trial in patients with recurrent NHL, Zevalin RIT was
well-tolerated and had a higher rate of overall and complete
responses compared to rituximab alone (Witzig et al., 2002b).
Zevalin RIT was also effective in rituximab-refractory NHL pa-
tients (Witzig et al., 2002a). Similar to rituximab, patients
eligible for Zevalin or Bexxar treatment are primarily selected
based on CD20 expression levels assessed by conventional
methods. However, particularly for RIT, molecular imaging
seems more appropriate, not only for assessing lymphoma
targeting but also for evaluating the distribution of CD20-
positive cells in non-tumor tissue (e.g. bone marrow) to esti-
mate toxicity levels. Because 90Y is a pure therapeutic b-
emitter, it requires a surrogate radioisotope (g-emitter), such
as 111In, for imaging. Thus for Zevalin imaging, ibritumomab
tiuxetan can be labeled with 111In, while for Bexxar the 131I-la-
bel can be used for both imaging and therapy since it emits
both b and g radiation. However, also for RIT, the predictive
value of CD20 imaging is not straightforward. In eight NHL pa-
tients with biopsy-proven CD20-positivity, 111In-ibritumomab
tiuxetan scans revealed that patients with the highest quanti-
tative concentration of lymph node radioactivity had a clinical
and FDG-PET/CT response upon Zevalin treatment (Jacobs
et al., 2009). However, another study in 19 NHL patients
showed no correlation between 111In-ibritumomab tiuxetan
uptake and Zevalin response (Gokhale et al., 2005). In 4 out
of 6 patients with PCNSL, tumor 111In-ibritumomab tiuxetan
accumulation was observed up to 5 days post-injection, in
contrast to another study using 123I-rituximab (Dietlein
et al., 2005; Maza et al., 2009) (Section 4.4). The discrepancy
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was ascribed to delayed antibody accumulation in some
PCNSL patients due to some remaining BBB function, which
could only be visualized by 111In-ibritumomab tiuxetan due
to a longer physical half-life, pointing out the importance of
selecting the appropriate radionuclide. The study showed
however no correlation between 111In-ibritumomab tiuxetan
tumor uptake and Zevalin response. Similar discordances
have been reported for Bexxar scans (Sgouros et al., 2003).
Because Zevalin and Bexxar are murine antibodies that might
induce human anti-mouse antibodies (HAMA), in general
these agents are not administrated repeatedly. To obviate
HAMA induction and allow repeated administration, several
studies radiolabeled the chimeric antibody rituximab (131I-rit-
uximab and 177Lu-rituximab) and investigated its RIT efficacy.
In a phase I/II 177Lu-rituximab trial of 29 lymphoma patients,
activity (overall response and stable disease (SD)) was re-
ported in 79% of patients (Forrer et al., 2013). In relapsed or re-
fractory NHL studies, 131I-rituximab RIT achieved high overall
and complete response rates with minimal toxicity and
repeated 131I-rituximab RIT increased the response rate and
duration compared to a single treatment (Kang et al., 2013;
Leahy et al., 2006; Turner et al., 2003). Prior to 131I-rituximab
RIT, imaging of a tracer activity of 131I-rituximab was per-
formed for individualized dosimetry tomonitor 131I-rituximab
distribution in these studies. Although this was primarily per-
formed to assess expected toxicity, these scans often visual-
ized target areas very clearly.
5.2. 177Lu-J591 and 90Y-J591
The J591 antibody is directed against the prostate-specific
membrane antigen (PSMA). PSMA expression is highly con-
stricted to prostate epithelium and is upregulated in prostate
cancer. Virtually all prostate cancers express PSMA and it is
considered a prostate-cancer restricted target. Although
J591 can be administered unlabeled for regular immuno-
therapy, best responses are seen at relatively high J591 doses
(100 mg) and the current opinion is that conjugation of J591
with toxins or radionuclides is a more promising approach
(Morris et al., 2005). For RIT purposes, J591 has been labeled
with 90Y or 177Lu in phase I studies in metastatic
castraction-resistant prostate cancer (CRPC) patients with
promising results (Tagawa et al., 2013; Vallabhajosula et al.,
2005b).
177Lu-J591 can be used for both imaging and therapy
because it emits both b and g radiation, while for 90Y-J591 im-
aging a surrogate radionuclide is required. A phase II study of
177Lu-J591 in CRPC patients demonstrated accurate tumor tar-
geting and prostate specific antigen (PSA) responses. Impor-
tantly, non-invasive assessment of PSMA expression by
imaging proved to be a predictive biomarker, since patients
with poor PSMA-imaging were less likely to respond to
177Lu-J591 therapy (Tagawa et al., 2013). For 177Lu-J591 and
90Y-J591 RIT patient selection, 111In-J591 imaging can be per-
formed since distribution patterns are generally comparable
and in this way no patient is exposed to a b-emitter in the
screening process (Kawano et al., 2010; Vallabhajosula et al.,
2005b). Multiple administrations of 177Lu-J591 or 90Y-J591
were tolerated (Vallabhajosula et al., 2005a).
5.3. 177Lu-girentuximab
Girentuximab binds to carbonic anhydrase IX (CAIX), a heat-
sensitive transmembranous glycoprotein, and is developed
for the treatment of RCC. Previous studies reported almost
ubiquitous expression (>90%) of CAIX in clear cell RCC
(ccRCC). Girentuximab has been successfully labeled to 111In,
131I and 124I, though intra-patient comparisons revealed
higher uptake of residualizing 111In-girentuximab prepara-
tions (Brouwers et al., 2005; Pryma et al., 2011). Thus for RIT,
higher radiation doses can be guided to tumor lesions with
residualizing radionuclides, such as 177Lu and 90Y. A phase I
study in metastatic ccRCC patients reported that 177Lu-giren-
tuximab RIT is well-tolerated, can be infused multiple times
and may stabilize previously progressive metastatic ccRCC
(Stillebroer et al., 2013). 111In-girentuximab was used for diag-
nostic imaging, and only patients with visible CAIX-targeting
received high-dose 177Lu-girentuximab RIT (n ¼ 23). Within
this group, 78% of patients responded (1 partial response
and 17 SD), which is superior over another study adminis-
tering two consecutive 131I-girentuximab treatments and indi-
cates the predictive value of 111In-girentuximab imaging
(Brouwers et al., 2005).
5.4. Gemtuzumab ozogamicin (Mylotarg)
Mylotarg is a CD33-mAb (gemtuzumab) linked to a toxin
belonging to the class of calicheamicins. CD33 is expressed
on themajority of myeloid leukemia cells, making it an attrac-
tive target for acute myeloid leukemia (AML). Mylotarg was
developed because lintizumab, an unconjugated CD33 anti-
body, showed only modest clinical activity with or without
chemotherapy. Mylotarg improved survival in a subset of
AML patients when combined with standard chemotherapy,
but the FDA requested withdrawal from the market due to
the results of a phase III trial in AML (Jurcic, 2012). In that
study, the addition of mylotarg to standard therapies resulted
in no survival benefits and more toxicity (Petersdorf et al.,
2013). Because CD33-targeting might still be of interest in
certain AML subsets, the introduction of predictive response
biomarkers could aid in selecting those patients that could
benefit from this treatment (Jurcic, 2012).
5.5. Trastuzumab emtansine (T-DM1, Kadcyla)
T-DM1 consists of the HER2-antibody trastuzumab (Section
4.1) linked to the potent toxin mertansine (DM1). In phase II
studies, T-DM1 was active in HER2-positive mBC patients re-
fractory to trastuzumab and lapatinib and led to improved
PFS compared to the combination of first-line trastuzumab
and docetaxel (Hurvitz et al., 2013; Krop and Winer, 2014). In
a recent phase III trial in HER2-positivemBC patients who pre-
viously received trastuzumab and a taxane, T-DM1 improved
the time to symptom worsening compared to capecitabine
and lapatinib (7.1 vs. 4.6 months) (Verma et al., 2012). Based
on the latter study, T-DM1 was recently FDA-approved for
HER2-positive mBC patients previously treated with trastuzu-
mab. Similar to trastuzumab monotherapy, patients were
selected based on HER2-expression by conventional methods,
although again HER2-positivity is at best a prerequisite.
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Molecular HER2 imaging might be of more predictive value,
which is the subject of an ongoing study investigating
whether 89Zr-trastuzumab PET/CT could identify HER2-
positive BC patients unlikely to benefit from T-DM1
(NCT01565200). The early identification of non-responders
could not only aid in avoiding unnecessary side-effects, but
could also be cost-effective because only patients likely to
benefit from T-DM1 treatment would be treated.
6. Summary and future prospects
Theranostics is a rapidly evolving approach in an era of
personalized and precision medicine. Especially because the
focus for treatment of most cancers is changing from rela-
tively low-cost chemotherapy to more expensive, targeted
therapies, predictive markers are not only a clinical necessity
but also an economic requirement. Application of an anti-
body for both diagnostic and therapeutic purposes is an
elegant approach for predicting and monitoring therapy
response. The first clinical studies, however, show some lim-
itations, of which the majority lie in the type of diagnostic
test used. Standard diagnostic tests such as IHC are per-
formed upon a single, often archival FFPE tumor section
and are unable to demonstrate whole tumor expression
levels, multiple lesions or target accessibility. This could in
part explain why these tests cannot accurately predict
response in all patients. Other IHC shortcomings are inter-
observer subjectivity and the difficulty to define subcellular
target localization. Functional antibody/antigen imaging mo-
dalities such as PET and SPECT can overcome all of these
shortcomings by only showing membranous expression
levels in all lesions. Moreover, these non-invasive whole
body scans can be carried out repetitively without the need
for repeated invasive biopsies. Although besides target
expression, especially for unconjugated antibody monothera-
pies, other growth compensatory mechanisms could influ-
ence the degree of response, this may be of less importance
for conjugated antibodies due to additional therapeutic radi-
ation or toxic effects. (Pre)clinical studies specifically
addressing the predictive value of imaging biomarkers are
however necessary, since not all radiolabeled antibodies
have equally predictive value.
Altogether, we believe that antibody theranostics are defi-
nitely promising for the future, but close attention should be
paid to the diagnostic test used for patient selection. Imple-
mentation of appropriate theranostics can significantly
improve efficacy, efficiency and cost-effectiveness of modern
cancer treatments.
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